Company intelligence / Profile preview

Mean Grit

Emeryville, California, United Statesgetthegrit.com ↗

Ownership: Private
Employees: ~134
Development stage: Preclinical

Overview

Gritstone’s lead program GRANITE showed a hazard ratio of 0.79 in phase II colorectal cancer studies but did not meet statistical significance at interim analysis. The SLATE program targets shared neoantigens in non-small cell lung cancer. Infectious disease vaccine candidates include COVID‑19 shots supported by BARDA funding, though trial delays have impacted progress. The company filed for bankruptcy after disappointing clinical results but continues to seek strategic alternatives or acquisition to continue R&D efforts

Therapeutic areas: OncologyInfectious Diseases
Modalities: Neoantigen cancer vaccine (Biologic)Tumor-infiltrating lymphocyte cell therapy (Cell therapy)CAR-NKT cell therapy (Cell therapy)In vivo CAR therapies (Gene therapy, Cell therapy)
Industry: Biotech

Partnerships

BARDA/U.S. government ("Project NextGen" for COVID vaccines)

Beyond the preview

Go deeper on Mean Grit.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mean Grit.

Explore the full profile